452 related articles for article (PubMed ID: 23561469)
1. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.
Herishanu Y; Katz BZ; Lipsky A; Wiestner A
Hematol Oncol Clin North Am; 2013 Apr; 27(2):173-206. PubMed ID: 23561469
[TBL] [Abstract][Full Text] [Related]
2. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
3. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
4. Modeling the chronic lymphocytic leukemia microenvironment in vitro.
Crassini K; Shen Y; Mulligan S; Giles Best O
Leuk Lymphoma; 2017 Feb; 58(2):266-279. PubMed ID: 27756161
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.
Ramsay AD; Rodriguez-Justo M
Br J Haematol; 2013 Jul; 162(1):15-24. PubMed ID: 23617880
[TBL] [Abstract][Full Text] [Related]
6. Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia.
Gimenez N; Tripathi R; Giró A; Rosich L; López-Guerra M; López-Oreja I; Playa-Albinyana H; Arenas F; Mas JM; Pérez-Galán P; Delgado J; Campo E; Farrés J; Colomer D
Sci Rep; 2020 Dec; 10(1):22153. PubMed ID: 33335123
[TBL] [Abstract][Full Text] [Related]
7. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
[TBL] [Abstract][Full Text] [Related]
8. Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?
Aydin E; Faehling S; Saleh M; Llaó Cid L; Seiffert M; Roessner PM
Front Immunol; 2020; 11():595818. PubMed ID: 33552053
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Hegde GV; Peterson KJ; Emanuel K; Mittal AK; Joshi AD; Dickinson JD; Kollessery GJ; Bociek RG; Bierman P; Vose JM; Weisenburger DD; Joshi SS
Mol Cancer Res; 2008 Dec; 6(12):1928-36. PubMed ID: 19074837
[TBL] [Abstract][Full Text] [Related]
10. Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.
Herman SE; Wiestner A
Semin Oncol; 2016 Apr; 43(2):222-32. PubMed ID: 27040700
[TBL] [Abstract][Full Text] [Related]
11. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.
Choi MY; Kashyap MK; Kumar D
Best Pract Res Clin Haematol; 2016 Mar; 29(1):40-53. PubMed ID: 27742071
[TBL] [Abstract][Full Text] [Related]
12. A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization.
Natoni A; O'Dwyer M; Santocanale C
Methods Mol Biol; 2013; 986():217-26. PubMed ID: 23436415
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
14. A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment.
Ferretti E; Bertolotto M; Deaglio S; Tripodo C; Ribatti D; Audrito V; Blengio F; Matis S; Zupo S; Rossi D; Ottonello L; Gaidano G; Malavasi F; Pistoia V; Corcione A
Leukemia; 2011 Aug; 25(8):1268-77. PubMed ID: 21546901
[TBL] [Abstract][Full Text] [Related]
15. Using the biology of chronic lymphocytic leukemia to choose treatment.
Hillmen P
Hematology Am Soc Hematol Educ Program; 2011; 2011():104-9. PubMed ID: 22160020
[TBL] [Abstract][Full Text] [Related]
16. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
17. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment.
Schulz A; Dürr C; Zenz T; Döhner H; Stilgenbauer S; Lichter P; Seiffert M
Blood; 2013 Mar; 121(13):2503-11. PubMed ID: 23349394
[TBL] [Abstract][Full Text] [Related]
20. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.
Troeger A; Johnson AJ; Wood J; Blum WG; Andritsos LA; Byrd JC; Williams DA
Blood; 2012 May; 119(20):4708-18. PubMed ID: 22474251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
